List of oncology APIs
Here is the list of oncology APIs for finished products circulating in the world
Please to provide us more APIs in case not up to date, vnras.com@gmail.com
List from Alex Chung
For more full list of oncology medicine granted registration numbers circulating in Vietnam.
UPDATED APRIL 27, 2018
| DCI | Classification | Vietnam |
| 5-fluorouracile | * | |
| Abiraterone | * | |
| Afatinib | * | |
| Aflibercept | ||
| Alemtuzumab (CD52, lymphocytes B et T) | Monoclonal antibodies against lymphocytes (target in parentheses) | |
| Altretamine | Other compounds | |
| Amsacrine | ||
| Anastrozol | Hormonal antagonists and aromatase inhibitors | * |
| Axitinib | ||
| Azacitidine | Pyrimidine analogs | |
| Azathioprime | Purine analogs and related inhibitors | |
| BCG lyophilise | Modulators of the host response | |
| Bendamustine | * | |
| Bevacizumab | Monoclonal antibodies against VEGF | |
| Bexarotene | ||
| Bicalutamid | Hormonal antagonists and aromatase inhibitors | * |
| Bleomycine | * | |
| Bortezomib | * | |
| Bosutinib | ||
| Brentuximab vedotin | ||
| Busereline | Hormonal antagonists and aromatase inhibitors | |
| Busulfan | Nitrogen Mustards | * |
| Cabazitaxel | ||
| Capecitabine | Pyrimidine analogs | * |
| Carboplatine | Platinum coordination complexes | * |
| Carmustine | Nitrosoureas | |
| Catumaxomab (CD3, lymphocytes B) | Monoclonal antibodies against lymphocytes (target in parentheses) | |
| Cetuximab (EGFR, HER1) | Monoclonal antibodies to HER receptors (target in parentheses) | |
| Chlorambucil | Nitrogen Mustards | |
| Chlormethine | Nitrogen Mustards | |
| Cisplatine | Platinum coordination complexes | * |
| Cladribine | Purine analogs and related inhibitors | |
| Clofarabine | Purine analogs and related inhibitors | |
| Crizotinib | ||
| Cyclophosphamide | Nitrogen Mustards | * |
| Cyproterone | Hormonal antagonists and aromatase inhibitors | * |
| Cytarabine | Pyrimidine analogs | * |
| Dabrafenib | ||
| Dacarbazine | Other compounds | |
| Dactinomycine | ||
| Dasatinib (Bcr-Abl) | Tyrosines kinases inhibitors (target in parentheses) | |
| Daunorubicine | Anthracyclines | * |
| Daunorubicine liposomale | * | |
| Decitabine | * | |
| Degarelix | Hormonal antagonists and aromatase inhibitors | * |
| Diethylstilbestrol | Hormonal antagonists and aromatase inhibitors | |
| Docetaxel | Alkaloids of l’If (taxanes) | * |
| Doxorubicine | Anthracyclines | * |
| Doxorubicine liposomale | * | |
| Doxorubicine liposomale pegylee | * | |
| Epirubicine | Anthracyclines | * |
| Eribuline | ||
| Erlotinib (HER1) | Tyrosines kinases inhibitors (target in parentheses) | * |
| Estramustine | Other compounds | |
| Etoposide | topoisomérase II inhibitors | * |
| Etoposide phosphate | ||
| Everolimus | mTOR kinase inhibitors | * |
| Exemestane | Hormonal antagonists and aromatase inhibitors | * |
| Fludarabine | Purine analogs and related inhibitors | * |
| Fluororuracile (5-FU) | Pyrimidine analogs | |
| Flutamide | Hormonal antagonists and aromatase inhibitors | |
| Fotemustine | Nitrosoureas | |
| Fulvestrant | Hormonal antagonists and aromatase inhibitors | * |
| Gefitinib (HER1) | Tyrosines kinases inhibitors (target in parentheses) | * |
| Gemcitabine | Pyrimidine analogs | * |
| Gosereline | Hormonal antagonists and aromatase inhibitors | * |
| Hydroxycarbamide | ||
| Hydroxyuree (hydroxycarbamide) | Other compounds | * |
| Ibritumomab (CD2, lymphocytes B) | Monoclonal antibodies against lymphocytes (target in parentheses) | |
| Idarubicine | Anthracyclines | * |
| Ifosfamide | Nitrogen Mustards | * |
| Imatinib (Bcr-Abl) | Tyrosines kinases inhibitors (target in parentheses) | * |
| Interferon-α (IFN-α) | Modulators of the host response | |
| Interleukine-2 (IL-2) | Modulators of the host response | |
| Ipilimumab | ||
| Irinotecan | Topoisomérase I inhibitors | * |
| Lanreotide | Hormonal antagonists and aromatase inhibitors | |
| Lapatinib (HER1/HER2) | Tyrosines kinases inhibitors (target in parentheses) | * |
| L-Asparaginase | ||
| Lenalidomide | * | |
| Letrozole | Hormonal antagonists and aromatase inhibitors | * |
| Leuprorelin acetate | Hormonal antagonists and aromatase inhibitors | * |
| Lomustine | Nitrosoureas | |
| Medroxyprogesterone | Hormonal antagonists and aromatase inhibitors | * |
| Megestrol | Hormonal antagonists and aromatase inhibitors | |
| Melphalan | Nitrogen Mustards | |
| Mercaptopurine | Purine analogs and related inhibitors | |
| Mesna | * | |
| Methotrexate | Antifolic acid analogs | * |
| Mitomycine C | Other compounds | |
| Mitoxantrone | Anthracenedione antineoplastic agent | * |
| Nab paclitaxel | ||
| Nelarabine | Purine analogs and related inhibitors | |
| Nilotinib (Bcr-Abl) | Tyrosines kinases inhibitors (target in parentheses) | * |
| Nilutamide | Hormonal antagonists and aromatase inhibitors | |
| Octreotide | Hormonal antagonists and aromatase inhibitors | * |
| Ofatumumab | ||
| Oxaliplatine | Platinum coordination complexes | * |
| Paclitaxel | Alkaloids of l’If (taxanes) | * |
| Panitumumab (EGFR, HER1) | Monoclonal antibodies to HER receptors (target in parentheses) | |
| Pazopanib | * | |
| Pemetrexed | Antifolic acid analogs | * |
| Pentostatine | Purine analogs and related inhibitors | |
| Pertuzumab | ||
| Pipobroman | Other compounds | |
| Pirarubicine | Anthracyclines | |
| Pomalidomide | ||
| Ponatinib | ||
| Procarbazine | Other compounds | |
| Raltitrexed | ||
| Regorafenib | * | |
| Rituximab (CD20, lymphocytes B) | Monoclonal antibodies against lymphocytes (target in parentheses) | |
| Ruxolitinib | * | |
| Sorafenib (multikinases) | Tyrosines kinases inhibitors (target in parentheses) | * |
| Streptozocine | Nitrosoureas | |
| Sunitinib (multikinases) | Tyrosines kinases inhibitors (target in parentheses) | * |
| Tamoxifene | Hormonal antagonists and aromatase inhibitors | * |
| Tegafur 25mg; Gimeracil 7,25mg; Oteracil kali 24,5mg | * | |
| Tegafur-uracile | Pyrimidine analogs | * |
| Temozolomide | Other compounds | * |
| Temsirolimus | mTOR kinase inhibitors | |
| Thalidomide | * | |
| Thioguanine | ||
| Thiotepa | Other compounds | |
| Topotecan | Topoisomérase I inhibitors | * |
| Toremifene | Hormonal antagonists and aromatase inhibitors | |
| Trabectedine | Other compounds | |
| Trastuzumab (HER2) | Monoclonal antibodies to HER receptors (target in parentheses) | |
| Tretinoine | * | |
| Trioxyde d’arsenic | ||
| Triptoreline | Hormonal antagonists and aromatase inhibitors | * |
| Vandetanib | ||
| Vemurafenib | ||
| Vinblastine | Alkaloids of Pervenche | |
| Vincristine | Alkaloids of Pervenche | * |
| Vindesine | Alkaloids of Pervenche | |
| Vinflunine | ||
| Vinorelbine | Alkaloids of Pervenche | * |
| Vismodegib |
